Cell Therapy Developer SBioMedics Raises 2 Billion Won in Paid-in Capital Increase... "For Operating Fund Procurement"
Esbiomedics, a KOSDAQ-listed cell therapy developer, announced on the 13th that it has decided to raise 2 billion KRW through a third-party allotment paid-in capital increase to secure operating funds and other expenses.
A total of 271,320 new common shares will be issued at a price of 25,800 KRW per share. The third-party allotment recipients include SYS Holdings (116,280 shares) and Dongkook Pharmaceutical (58,140 shares), among others.
Hot Picks Today
"'Samsung Electronics Preferred Shares' Bought on Margin, 130 Million Won in Dividends Alone... 2 Billion Won Windfall for Teacher Couple Born in 1993"
- [Exclusive] Prostitution Near Elementary Schools for 18 Years... Police Seize Even the Beds
- Their Life Savings of 1.5 Billion Won Nearly Lost in an Instant... Police Prevent Voice Phishing Scam Targeting Elderly Couple in Their 80s
- 254 Dead but "Index Case Still Unknown" as Ebola Outbreak Reaches Record Severity
- Fully Shielded with Hat and Mask: Chinese Woman Develops Rash While Trying to Avoid UV Rays
The company stated that the purpose of the third-party allotment capital increase is "to achieve management objectives through operating funds and other funds (clinical trial costs)."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
